SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on September 23, 2011, reporting events occurring on September 20, 2011. The filing discloses the entry into a material definitive agreement regarding executive compensation. Note: The request metadata referenced "AIM Immunotech Inc.," but the filing text explicitly identifies the registrant as Hemispherx Biopharma, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on a specific employment agreement.
Material Changes and Executive Compensation
The Company entered into an amended and restated employment agreement with Dr. Ralph Christopher Cavalli, Ph.D., Vice President of Quality Control. Key terms include:
- Term: Expires March 15, 2013, with automatic one-year renewals unless notice is given 90 days prior.
- Base Salary: Remains at $180,264 annually, subject to cost of living increases.
- Performance Bonus: Up to 20% of base salary, at the discretion of the Compensation Committee.
- Stock Options: Grant of non-qualified options to purchase 40,000 shares.
- Option Terms: Exercisable over 10 years; vests ratably over 18 months; exercise price set at 110% of the closing price on September 14, 2011.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The only contingency noted is the potential for termination of the agreement for cause, death, or disability, or via 30 days' prior written notice by Dr. Cavalli.
Investor Verification Checklist
- Verify the closing price of Hemispherx Biopharma common stock on September 14, 2011, to calculate the specific exercise price of the 40,000 options.
- Confirm the vesting schedule details in the attached Exhibit 10.1 (Amended and Restated Cavalli Employment Agreement).
- Review the Compensation Committee's historical bonus payout practices to assess the likelihood of the 20% performance bonus.
- Check subsequent filings for any changes to Dr. Cavalli's employment status or the Company's capital structure.